Skip NavigationSkip to Content
Return Return to Search Results

A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model

  1. Author:
    Kiyuna, Tasuku
    Tome, Yasunori
    Murakami, Takashi
    Miyake, Kentaro
    Igarashi, Kentaro
    Kawaguchi, Kei
    Oshiro, Hiromichi
    Higuchi, Takashi
    Miyake, Masuyo
    Sugisawa, Norihiko
    Zhang, Zhiying
    Razmjooei, Sahar
    Wangsiricharoen, Sintawat
    Chmielowski, Bartosz
    Nelson, Scott D
    Russell, Tara A
    Dry, Sarah M
    Li, Yunfeng
    Eckardt, Mark A
    Singh, Arun S
    Chawla, Sant
    Kanaya, Fuminori
    Eilber, Fritz C
    Singh, Shree Ram
    Zhao, Ming
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan., Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address: yash_toume@hotmail.com., AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., AntiCancer Inc, San Diego, CA, USA., Div. of Hematology-Oncology, University of California, Los Angeles, CA, USA., Department of Pathology, University of California, Los Angeles, CA, USA., Division of Surgical Oncology, University of California, Los Angeles, CA, USA., Department of Surgery, Yale School of Medicine, New Haven, CT, USA., Sarcoma Oncology Center, Santa Monica, CA, USA. Electronic address: santchawla@gmail.com., Division of Surgical Oncology, University of California, Los Angeles, CA, USA. Electronic address: fceilber@mednet.ucla.edu., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2018
    2. Date: Nov 2
    3. Epub Date: 2018 10 03
  2. Journal: Biochemical and biophysical research communications
    1. 505
    2. 3
    3. Pages: 733-739
  4. Type of Article: Article
  5. ISSN: 0006-291X
  1. Abstract:

    Myxofibrosarcoma (MFS) is the most common sarcomas in elderly patients and is either chemo-resistant or recurs with metastasis after chemotherapy. This recalcitrant cancer in need of improved treatment. We have established a patient-derived orthotopic xenograft (PDOX) of MFS. The MFS PDOX model was established in the biceps femoris of nude mice and randomized into 7 groups of 7 mice each: control; doxorubicin (DOX); pazopanib (PAZ); temozolomide (TEM); Irinotecan (IRN); IRN combined with TEM; IRN combined with cisplatinum (CDDP) and Salmonella typhimurium A1-R (S. typhimurium A1-R). Treatment was evaluated by relative tumor volume and relative body weight. The MFS PDOX models were DOX, PAZ, and TEM resistant. IRN combined with TEM and IRN combined with CDDP were most effective on the MFS PDOX. S. typhimurium A1-R arrested the MFS PDOX tumor. There was no significant body weight loss in any group. The present study suggests that the combination of IRN with either TEM or CDDP, and S. typhimurium have clinical potential for MFS. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.bbrc.2018.09.106
  3. PMID: 30292411
  4. View record in Web of Science®
  5. WOS: 000449244000015
  6. PII : S0006-291X(18)32033-3

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel